NYSE:ENZ (USA) Also trade in: Germany UK

Enzo Biochem Inc

$ 3.01 -0.13 (-4.14%)
Volume: 269,850 Avg Vol (1m): 225,699
Market Cap $: 143.15 Mil Enterprise Value $: 83.33 Mil
P/E (TTM): 75.25 P/B: 1.56
Earnings Power Value 0.32
Net Current Asset Value 1.39
Tangible Book 1.75
Projected FCF 2.72
Median P/S Value 3.43
Graham Number 1.25
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7.3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 15.12
Cash-To-Debt range over the past 10 years
Min: 0.01, Med: 285.95, Max: 10000
Current: 15.12
0.01
10000
Equity-to-Asset 0.82
Equity-to-Asset range over the past 10 years
Min: 0.01, Med: 0.85, Max: 0.97
Current: 0.82
0.01
0.97
Debt-to-Equity 0.05
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.08, Max: 53.43
Current: 0.05
0
53.43
Debt-to-EBITDA -0.18
Debt-to-EBITDA range over the past 10 years
Min: -0.4, Med: -0.3, Max: 1.27
Current: -0.18
-0.4
1.27
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.82
DISTRESS
GREY
SAFE
Beneish M-Score -3.85
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -104.99%
WACC 10.31%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -31.42
N/A
Net Margin % 2.44
Net Margin range over the past 10 years
Min: -38.09, Med: -11.55, Max: 44.06
Current: 2.44
-38.09
44.06
ROE % 2.63
ROE range over the past 10 years
Min: -56.99, Med: -16.22, Max: 68.53
Current: 2.63
-56.99
68.53
ROA % 2.11
ROA range over the past 10 years
Min: -43.97, Med: -13.85, Max: 50.26
Current: 2.11
-43.97
50.26
ROC (Joel Greenblatt) % -180.56
N/A
3-Year Total Revenue Growth Rate 2.40
3-Year Revenue Growth Rate range over the past 10 years
Min: -15.7, Med: 3.6, Max: 24.5
Current: 1.2
-15.7
24.5
3-Year Total EBITDA Growth Rate -0.60
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 0.7, Max: 206.1
Current: 0.7
0
206.1
3-Year EPS w/o NRI Growth Rate -63.90
N/A

Ratios

Current vs industry vs history
PE Ratio (TTM) 75.25
PE Ratio range over the past 10 years
Min: 5.25, Med: 12.31, Max: 101.75
Current: 75.25
5.25
101.75
PE Ratio without NRI 75.25
PE without NRI range over the past 10 years
Min: 5.25, Med: 12.31, Max: 101.75
Current: 75.25
5.25
101.75
PB Ratio 1.56
PB Ratio range over the past 10 years
Min: 0.84, Med: 2.56, Max: 6.86
Current: 1.56
0.84
6.86
PS Ratio 1.64
PS Ratio range over the past 10 years
Min: 0.56, Med: 1.87, Max: 5.07
Current: 1.64
0.56
5.07
Price-to-Operating-Cash-Flow 25.51
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.48, Med: 13.79, Max: 253.46
Current: 25.51
4.48
253.46
EV-to-EBIT -3.06
EV-to-EBIT range over the past 10 years
Min: -168.8, Med: -8.4, Max: -2.2
Current: -3.06
-168.8
-2.2
EV-to-EBITDA -3.46
EV-to-EBITDA range over the past 10 years
Min: -1024, Med: -9.4, Max: 1076.2
Current: -3.46
-1024
1076.2
EV-to-Revenue 0.96
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 1.4, Max: 4.5
Current: 0.96
0.4
4.5
Current Ratio 5.61
Current Ratio range over the past 10 years
Min: 0.2, Med: 5.41, Max: 33.9
Current: 5.61
0.2
33.9
Quick Ratio 5.12
Quick Ratio range over the past 10 years
Min: 0.17, Med: 4.79, Max: 33.15
Current: 5.12
0.17
33.15
Days Inventory 46.78
Days Inventory range over the past 10 years
Min: 43.01, Med: 58.71, Max: 64.59
Current: 46.78
43.01
64.59
Days Sales Outstanding 48.16
Days Sales Outstanding range over the past 10 years
Min: 45.29, Med: 49.48, Max: 54.54
Current: 48.16
45.29
54.54
Days Payable 40.33
Days Payable range over the past 10 years
Min: 29.18, Med: 56.99, Max: 63.52
Current: 40.33
29.18
63.52

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.20
3-Year Share Buyback Rate range over the past 10 years
Min: -20, Med: -3, Max: -0.4
Current: -1.2
-20
-0.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.72
Price-to-Tangible-Book range over the past 10 years
Min: 1.94, Med: 5.01, Max: 124.5
Current: 1.72
1.94
124.5
Price-to-Projected-FCF 1.11
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.28, Med: 3.98, Max: 26.21
Current: 1.11
1.28
26.21
Price-to-Median-PS-Value 0.88
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 2.78, Max: 25.77
Current: 0.88
0.2
25.77
Price-to-Graham-Number 2.41
Price-to-Graham-Number range over the past 10 years
Min: 0.99, Med: 4.36, Max: 21.06
Current: 2.41
0.99
21.06
Earnings Yield (Joel Greenblatt) % -32.68
Earnings Yield (Greenblatt) range over the past 10 years
Min: -45.1, Med: -11.8, Max: -0.6
Current: -32.68
-45.1
-0.6
Forward Rate of Return (Yacktman) % 8.81
Forward Rate of Return range over the past 10 years
Min: -31.2, Med: -8.6, Max: 16.7
Current: 8.81
-31.2
16.7

» ENZ's 30-Y Financials

Financials (Next Earnings Date: 2019-10-16)

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:ENZ

Business Description

Industry Medical Diagnostics & Research » Medical Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare LSE:EKF AMEX:VNRX LSE:RENX TSE:6678 AMEX:PTN LSE:AGL NAS:STIM HKSE:08037 XKRX:245620 TSE:4671 NAS:CELC TSE:4595 TSE:4978 NAS:CTSO XKRX:038290 TSX:AKU.U ASX:VHT AMEX:SENS MEX:MEDICA B OSTO:CRAD B
Traded in other countries EZB.Germany 0IHV.UK
Address 527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

More Statistics

Revenue (TTM) (Mil) $ 86.7
EPS (TTM) $ 0.04
Beta 1.47
Volatility % 61.1
52-Week Range $ 2.32 - 5
Shares Outstanding (Mil) 47.19

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N